Oxycodone is a semi-synthetic opioid that is structurally similar to codeine and equipotent to morphine in producing analgesic effects. Oxycodone has been prescribed in many immediate-release formulations including Percodan | Percocet ~, Tylox | Roxicodone | and Toxicet ~. In 1995, the Food and Drug Administration approved Oxycontin, a controlled-release form of oxycodone. Although the immediate-release forms of oxycodone can be prescribed in doses of 10-30 mg every 4 b, it is recommended that Oxycontin be prescribed in doses of 10-160 mg every 12 h. In a six-year period, the Los Angeles County Department of Coroner's Toxicology Laboratory detected oxycodone in 67 cases, 36 of which were determined to be the controlled-release form. The objectives of this paper are to provide general information about Oxycontin, including postmortem tissue distributions of oxycodone in cases in which the controlled-release form was identified, and to introduce the concept of ghost pills. A ghost pill is a seemingly intact but drug-free tablet that resembles an undigested pill The isolation and identification of oxycodone from postmortem specimens was achieved using a basic, liquid-liquid extraction with screening and quantitation by gas chromatography-nitrogen-phosphorus detection and gas chromatography-mass spectrometry, respectively. Oxycodone-d 3 was used as an internal standard for quantitation. The assays were linear from 0.10 to 5.0 mg/L. The tissue distribution ranges of oxycodone in the 36 case examples were heart blood 0.12-46 mg/L (36), femoral blood +< 0.10-13 mg/L (35), liver 0.11-6.1 mg/kg (16), urine 2.5-122 mg/L (22), bile 0.19-49 mg/L (15), vitreous 0.24-0.82 mg/L (6), and gastric 0.06-119 mg total (21).
Introduction
Oxycontin is the controlled-release form of oxycodone hydrochloride ( Figure 1) (1). Oxycontin was developed by Purdue Pharma L.P. and was approved for production by the Food and Drug Administration in December 1995. It was initially prescribed in 10-, 20-, 40-, 80-, and 160-rag tablets every 12 h, but in 2001, Purdue Pharma L.P. discontinued distributing the 160-mg tablet. Oxycontin is indicated for the management of moderate to severe pain where the use of an opioid analgesic is required for more than a few days. The tablets are designed to provide a controlled delivery of oxycodone over a 12-h period (2) . This prolonged release is achieved using the Acro-Contin | drug-delivery system. It utilizes a dual-control matrix consisting of two hydrophobic macromolecules and an acry]ic polymer. Oxycodone is delivered from the tablets in a biphasic fashion with an initial rapid release of drug from the tablet surface followed by the slow release of the remainder of oxycodone by its dissolution through the tablet matrix over the 12-h dosing period (3) . The release of oxycodone from this system is pH independent and is not affected by food (2) .
Oxycodone is an opioid alkaloid painkiller derived from thebaine, structurally similar to codeine, and equipotent to morphine in producing analgesic effects. Oxycodone is also available in the immediate-release form of lO-30-mg preparations and is prescribed for use up to four times a day. Oxycodone is well absorbed with oral bioavailability from 60 to 87%, Peak serum 
CH3 MW 351.83
concentrations after a single 20-mg controlled-release dose averaged 0.023 mg/L at 3.2 h and, for a 40-or 80-mg tablet, averaged 0.039 and 0.099 rag/L, respectively. The absorption half-life for the immediate-release form is 0.4 h, and the controlled release form is 0.6 h for the first phase and 6.9 h for the second phase (4) . Steady-state concentrations are achieved within 24-36 h after repeated dosing of normal volunteers.
Oxycodone is metabolized to oxymorphone and is eliminated primarily in the urine as both the conjugated and unconjugated metabolites. The elimination half-life of the immediate release oxycodone is 3.2 h and 4.5 h for the controlled release form.
Oxycodone is distributed to the skeletal muscle, the intestinal tract, lungs, spleen, and brain (2) .
Experimental

Specimens
All specimens were collected at the time of autopsy. Heart blood samples were preserved with sodium fluoride while peripheral blood samples were collected from the femoral vein and preserved with sodium fluoride and potassium oxylate. Other autopsy specimens such as liver, urine, bile, vitreous, and gastric contents were submitted and stored without preservative. All liver specimens were homogenized in a blender; dry specimens were diluted (1:1, w/v) with distilled water. Intact tablets were removed prior to homogenization of the entire gastric sample. All specimens were stored at 4~
Materials
Oxycodone hydrochloride, courtesy of Endo Laboratories, was prepared as a 1-mg/mL stock solution of free oxycodone in methanol. Oxycodone-d3 and carbinoxamine were used as internal standards and were obtained from Cerilliant and McNeil Laboratories, respectively. The derivatizing agent, N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was manufactured by Sigma-Aldrich. All reagents were analytical grade and were purchased from various vendors.
Extraction
To 2 mL of spiked calibrators prepared in porcine blood, blood specimen, or tissue homogenate were added internal standard (100 IJL of carbinoxamine (15 rag/L) for screening or 25 IJL of oxycodone-d3 (25 mg/L) for quantitation), and 2 mL buffer (20% sodium carbonate). The samples were vortex mixed for 30 s prior to the addition of 6-mL n-butylchloride. After rotation for 20 min and centrifugation, the organic layer was separated. Two milliliters of 0.10N hydrochloric acid was added to the organic layer, and the sample was vortex mixed for 20 s. Following centrifugation and aspiration of the organic layer to waste, the aqueous layer was washed with 4 mL 2-methylbutane by vortex mixing for 15 s. The organic layer was aspirated to waste. The aqueous layer was made alkaline with i mL 20% sodium carbonate buffer and extracted with 4 mL 2-methylbutane by vortex mixing for 20 s. The organic layer was evaporated to dryness, the residue was either reconstituted with 75 IJL of methanol for screening or derivatized for 30-45 rain with 50 I~L MSTFA (TMS) for quantitation, and transferred to autosampler vials for instrumental analysis.
Instrumentation
A Hewlett-Packard (HP) model 6890 gas chromatograph (GC) with a nitrogen-phosphorus detector (NPD), with a 7683 autosampler, was used for presumptive identification. Dual column separation was achieved using two capillary columns, an HP-5 (15 m x 0.25-mm i.d., 0.25-1~m film thickness) and an HP-35 (15 m x 0.25-mm i.d., 0.25-~m film thickness). The oven temperatures were programmed at 140~ for 0.50 rain, increased to 300~ at 10~ and held for 10.5 rain (total analysis time of 27 rain). The injector temperature was 260~ and the detector temperatures were 325~
Confirmation
Confirmation was achieved with an HP model 6890 GC equipped with a 5973 mass selective detector (MSD) and a 7683 autosampler. The MSD was operated in the electron impact ionization mode with a full-scan mass-to-charge ratio range of 40-450 ainu. An HP-5 (15 m x 0.25-ram i.d., 0.25-1Jm film thickness) capillary column was used. The oven temperature was programmed at 10~ from 120~ to 300~ and held for 2 rain (total analysis time of 20 min). The injection and detection temperatures were 250~ and 300~ respectively. The mass spectrum of oxycodone showed a base peak ofm/z 315 and other significant ions at m/z 230, 115, and 201.
Quantitation
Quantitation was achieved with an MSD equipped with an HP-5 column with the oven temperature programmed at 10~ from 200~ to 300~ The injection and detection temperatures were 250~ and 300~ respectively. The ions used for the quantitation of oxycodone were 387, 372, and 388 for the TMS-derivative or 459, 444, and 312 for the di-TMS derivative. Oxycodone-d3 was used as the internal standard and the ions monitored were 390, 375, and 391 or 462, 447, and 315 for the TMS and di-TMS derivatives, respectively. In this study, early quantitations used the ions of the TMS derivative, and the later analyses used the ions of the di-TMS derivative. Comparisons were made between the TMS and di-TMS derivatives and the quantitative results were equivalent.
Results
Tissue specimens were collected during autopsy and submitted for routine toxicology testing. The time interval between death and autopsy varied from 24 to 72 h. Heart blood samples were tested for volatfles by headspace GC, screened for drugs of abuse by radioimmunoassay or ELISA, and analyzed for pharmaceutical drugs by GC-NPD. Oxycodone was presumptively identified from a basic extraction by GC-NPD and confirmed by gas chromatography-mass spectrometry (GC-MS). Quantitation of oxycodone was performed on a second aliquot of specimen and analyzed by GC-MS. Assays were linear from 0.10 to 5.0 mg/L. Case histories, postmortem oxycodone (Oxycontin) tissue distributions, other heart blood drug levels, and the cause and manner of death for 36 cases are detailed in Table I .
Although oxycodone has been available since 1917, the controlled-release formula, Oxycontin, is relatively new and has quickly gained popularity as a drug of abuse (5) . Since 1996, the Los Angeles County Department of Coroner's Toxicology Laboratory detected Oxycontin in 36 cases with 24 of those cases recorded in the last 2 years. For summary purposes, the 36 cases have been organized according to the mode of death. There were 20 accidental deaths, 10 suicides, 4 natural deaths, and 2 undetermined deaths. The 20 accidental deaths had oxycodone heart and femoral blood levels that ranged from 0.12 to 2.7 mg/L and +< 0.t0 to 2.2 mg/L, respectively. The 10 suicides had heart and femoral blood ranges of 0.56-46 mg/L and 0.59-13 rag/L, respectively. The four natural deaths had a heart blood range of 0.14-1.0 rag/L, and the two undetermined cases had oxycodone heart blood levels of 0.27 and 1.3 mg/L. It should be noted that in 4 of the 36 cases (cases 2, 7, 21, and 25) the femoral oxycodone levels were almost twice that of the heart blood. The authors can only attribute this discrepancy to sample collection technique. A review of the 36 cases yields interesting information about this controlled-release delivery system of oxycodone.
Discussion
Oxycontin was first encountered by the authors in 1999 when numerous intact tablets were identified in the stomach contents of several postmortem cases. Of the 36 cases presented in this paper, intact tablets were found in 15 cases. Frequently, cases with intact pills or residue in the stomach coupled with lethal blood drug levels are interpreted to be suicides by the Los Angeles County Department of Coroner Toxicology Laboratory. This way of evaluating casework may be incorrect when a timerelease formulation is involved.
According to Purdue Pharma L.P., the co-polymer wax matrix of Oxycontin is not meant to dissolve. A small amount of oxycodone is immediately released as the outside layer surrounding the matrix dissolves postingestion (3). The remaining oxycodone in the tablet leaches out of the matrix and is delivered over a 12-h period, leaving behind an intact, drug-free wax matrix referred to as a "ghost pill" (6) . In many of the cases studied, intact ghost pills in the stomach contents were clearly marked with an "OC" on one side and a number indicating dose on the other. An analysis of some of the recovered Oxycontin tablets from the stomach revealed little or no oxycodone present, supporting the theory that the remaining intact tablets are ghost pills.
In 18 of the 36 cases studied, at least one other opiate in addition to oxycodone was detected. Of the 18 multi-opiate cases, intact tablets were recovered from the stomach in 9 cases. The authors postulate that because opiates reduce gastric motility, oxycodone may build-up in the stomach and decrease the ability to clear the tablets. The authors also suggest that because Oxycontin is a controlled-release tablet, oxycodone continues to leach out of the tablet after death, which may lead to a falsely elevated stomach concentration. In the cases studied, however, the gastric concentration of oxycodone was considerably less than expected in comparison with the number of remaining intact tablets. This suggests that oxycodone is being cleared from the stomach, antemortem, while the "ghost pills,' remain. Although the death may still be an oxycodone overdose, intact tablets in the stomach may not necessarily indicate a suicide. Moreover, because Oxycontin tablets are not meant to dissolve, it is not possible to correlate the number of tablets recovered in the stomach to inappropriate use of the drug.
The authors can only speculate as to why an increased number of tablets were discovered in the gastric contents of so many of the cases presented. Perhaps, individuals may be accustomed to taking multiple doses of another type of pain medication. In doing so, they may be used to immediate pain relief upon dosing and therefore take additional Oxycontin when the initial analgesia appears less than effective. As a result, there is concern that those taking Oxycontin are not well informed about the controlled-release system of drug delivery. It was also noted during case evaluation that doctors may be over-prescribing Oxycontin. Despite the manufacturer's recommendation that dosing should occur over a 12-h period, prescriptions for the administration of Oxycontin 3, 4, and even 6 times a day were found in 12 of the 36 cases studied. Again, the lack of understanding about this controlled-release delivery system may be a reason for the recovery of so many intact tablets from the stomach. Of course, the possibility that individuals may have taken an intentional overdose of Oxycontin in a suicidal gesture cannot be ruled out.
